Comparing survival predicted by the diagnosis-specific Graded Prognostic Assessment (DS-GPA) to actual survival in patients with 1 –10 brain metastases treated with stereotactic radiosurgery

Of all patients diagnosed with cancer, 8 –10% will develop brain metastases (BM) [1]. This incidence is expected to increase with more effective treatments for the primary tumours, thereby improving survival and thus increasing the time for possible dissemination of tumour to the brain [1,2]. Brain metastases most frequently originate fr om lung cancer, breast cancer and melanoma [1–5], but in up to 14% of patients, the metastases are of unknown origin [3–5].

Source: Radiotherapy and Oncology - July 10, 2019 Category: Radiology Authors: Steven Nagtegaal, An Claes, Karijn Suijkerbuijk, Franz Schramel, Tom Snijders, Joost Verhoeff Tags: Original Article Source Type: research